Literature DB >> 1796398

Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.

H R Lijnen1, J M Stassen, I Vanlinthout, H Fukao, K Okada, O Matsuo, D Collen.   

Abstract

The thrombolytic and pharmacokinetic properties of staphylokinase were compared with those of streptokinase in hamsters with a pulmonary embolus produced from human plasma or from hamster plasma, and in rabbits with a jugular vein blood clot produced from rabbit blood. In both models, a continuous intravenous infusion of staphylokinase and streptokinase over 60 min in hamsters or over 4 h in rabbits, induced dose-dependent progressive clot lysis in the absence of significant systemic activation of the fibrinolytic system. The results of thrombolytic potency (clot lysis at 30 min after the end of the infusion, in percent, versus dose administered, in mg/kg) were fitted with an exponentially transformed sigmoidal function (formula: see text) and the maximal percent clot lysis (c), the maximal rate of lysis (z = 1/4 ac.eb) and the dose at which the maximal rate of lysis is achieved (b) were determined. In hamsters with a pulmonary embolus produced from human plasma, streptokinase had a somewhat higher thrombolytic potency than staphylokinase, as revealed by a higher z value (2,100 +/- 1,100% lysis per mg/kg streptokinase administered versus 1,100 +/- 330% lysis per mg/kg for staphylokinase). In hamsters with a pulmonary embolus produced from hamster plasma, staphylokinase had a somewhat higher thrombolytic potency than streptokinase (z = 1,600 +/- 440 versus 1,200 +/- 370% lysis per mg/kg). Staphylokinase had a higher thrombolytic potency than streptokinase in rabbits,as revealed by a higher z-value (950 +/- 350% lysis per mg/kg staphylokinase administered versus 330 +/- 39% lysis per mg/kg for streptokinase) and a lower b-value (0.035 +/- 0.010 mg/kg staphylokinase versus 0.091 +/- 0.008 mg/kg for streptokinase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1796398

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

3.  Molecular analysis of human and canine Staphylococcus aureus strains reveals distinct extended-host-spectrum genotypes independent of their methicillin resistance.

Authors:  S Vincze; I Stamm; S Monecke; P A Kopp; T Semmler; L H Wieler; A Lübke-Becker; B Walther
Journal:  Appl Environ Microbiol       Date:  2012-11-16       Impact factor: 4.792

Review 4.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

5.  Identification of a new exosite involved in catalytic turnover by the streptokinase-plasmin activator complex during human plasminogen activation.

Authors:  Rachna Aneja; Manish Datt; Balwinder Singh; Shekhar Kumar; Girish Sahni
Journal:  J Biol Chem       Date:  2009-09-30       Impact factor: 5.157

Review 6.  Thrombolytic agents and anticoagulants.

Authors:  R C Becker
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

Review 7.  Novel thrombolytic agents.

Authors:  M Verstraete; H R Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

8.  Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.

Authors:  Marijke Peetermans; Thomas Vanassche; Laurens Liesenborghs; Jorien Claes; Greetje Vande Velde; Jakub Kwiecinksi; Tao Jin; Bart De Geest; Marc F Hoylaerts; Roger H Lijnen; Peter Verhamme
Journal:  BMC Microbiol       Date:  2014-12-17       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.